LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)

被引：4
|
作者：
El-Khoueiry, Anthony B.
Llovet, Josep M.
Vogel, Arndt
Madoff, David C.
Finn, Richard S.
Ogasawara, Sadahisa
Ren, Zhenggang
Mody, Kalgi
Li, Jerry J.
Siegel, Abby B.
Dubrovsky, Leonid
Kudo, Masatoshi
机构：
[1] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[3] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Catalonia, Spain
[4] Inst Catalana dEstudis Avancats ICREA, Barcelona, Spain
[5] Hannover Med Sch, Hannover, Germany
[6] Smilow Canc Hosp, Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[7] Smilow Canc Hosp, Yale New Haven Hlth, New Haven, CT USA
[8] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[9] Chiba Univ, Grad Sch Med, Chiba, Japan
[10] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[11] NJ Merck Co Inc, Woodcliff Lake, Kenilworth, NJ USA
[12] Kindai Univ, Sch Med, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS494
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS494
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol (Mar, 10.1007/s00270-021-03010-0, 2022)
    Fidelman, Nicholas
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2022, 45 (05) : 719 - 719
  • [42] A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
    Sangro, Bruno
    Harding, James J.
    Johnson, Matthew
    Palmer, Daniel H.
    Edeline, Julien
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Decaens, Thomas
    El-Khoueiry, Anthony B.
    Finn, Richard S.
    Galle, Peter R.
    Park, Joong-Won
    Yau, Thomas
    Begic, Damir
    Shen, Yun
    Neely, Jaclyn
    Sama, Ashwin Reddy
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [43] Efficacy of local-regional treatment plus sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
    Hong, Tzu-Chun
    Tsai, Hong-Ming
    Lin, Yih-Jyh
    Chen, Chiung-Yu
    Chuang, Chiao-Hsiung
    Wu, I-Chin
    Chang, Ting-Tsung
    Han, Meng-Zhi
    Lin, Sheng-Hsiang
    Chen, Shang-Hung
    Wang, Hao-Chen
    Chen, Po-Jun
    Hsieh, Ming-Tsung
    Chiang, Hsueh-Chien
    Liu, Chieh-Yen
    Kuo, Hsin-Yu
    ADVANCES IN DIGESTIVE MEDICINE, 2023, 10 (02) : 71 - 79
  • [44] Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate-stage hepatocellular carcinoma: A pilot study
    Huo, Haoran
    Wang, Xiaoying
    Xu, Shan
    Niu, Xiaotong
    Cheng, Limin
    Yuan, Zengjiang
    Huo, Shuang
    Fang, Pingping
    ONCOLOGY LETTERS, 2023, 26 (05)
  • [45] Survival and prognostic factors in patients with intermediate stage hepatocellular carcinoma (HCC) who were treated with repeated transarterial chemoembolization (TACE)
    Kim, Jung hee
    Jeong, Woo Kyoung
    Sohn, Won
    Paik, Yong-Han
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    HEPATOLOGY, 2015, 62 : 453A - 453A
  • [46] Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
    Arizumi, Tadaaki
    Ueshima, Kazuomi
    Minami, Tomohiro
    Kono, Masashi
    Chishina, Hirokazu
    Takita, Masahiro
    Kitai, Satoshi
    Inoue, Tatsuo
    Yada, Norihisa
    Hagiwara, Satoru
    Minami, Yasunori
    Sakurai, Toshiharu
    Nishida, Naoshi
    Kudo, Masatoshi
    LIVER CANCER, 2015, 4 (04) : 253 - 262
  • [47] Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases
    Izumoto, Hirofumi
    Hiraoka, Atsushi
    Ishimaru, Yoshihiro
    Murakami, Tadashi
    Kitahata, Shogo
    Ueki, Hidetaro
    Aibiki, Toshihiko
    Okudaira, Tomonari
    Miyamoto, Yuji
    Yamago, Hiroka
    Iwasaki, Ryuichiro
    Tomida, Hideomi
    Mori, Kenichiro
    Kishida, Masato
    Tsubouchi, Eiji
    Miyata, Hideki
    Ninomiya, Tomoyuki
    Kawasaki, Hideki
    Hirooka, Masashi
    Matsuura, Bunzo
    Abe, Masanori
    Hiasa, Yoichi
    Michitaka, Kojiro
    Kudo, Masatoshi
    ONCOLOGY, 2017, 93 : 120 - 126
  • [48] Radiologic Patterns Determine the Outcomes of Initial and Subsequent Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
    Hung, Ya-Wen
    Lee, I-Cheng
    Chi, Chen-Ta
    Lee, Rheun-Chuan
    Liu, Chien-An
    Chiu, Nai-Chi
    Hwang, Hsuen-En
    Chao, Yee
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    LIVER CANCER, 2024, 13 (01) : 29 - 40
  • [49] Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
    Hatanaka, Takeshi
    Yata, Yutaka
    Naganuma, Atsushi
    Kakizaki, Satoru
    CANCERS, 2023, 15 (06)
  • [50] Post progression survival in patients with intermediate-stage hepatocellular carcinoma after receiving transarterial chemoembolization
    Shima, Yukiko
    Ogasawara, Sadahisa
    Ooka, Yoshihiko
    Kobayashi, Kazufumi
    Maruta, Susumu
    Kanzaki, Hiroaki
    Kanayama, Kengo
    Maeda, Takahiro
    Kusakabe, Yuko
    Kiyono, Soichiro
    Nakamura, Masato
    Saito, Tomoko
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Yasui, Shin
    Tawada, Akinobu
    Chiba, Tetsuhiro
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Naoya
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E75 - E75
12345